+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Thrombolytic Drug Market by Drug Class, Indication, Route Administration, End User, Patient Group - Global Forecast to 2030- Product Image
Thrombolytic Drug Market by Drug Class, Indication, Route Administration, End User, Patient Group - Global Forecast to 2030- Product Image
Sale

Thrombolytic Drug Market by Drug Class, Indication, Route Administration, End User, Patient Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5612901
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The thrombolytic drug market is undergoing rapid evolution, driven by clinical innovation, strategic collaborations, and heightened regulatory scrutiny. As healthcare organizations and pharmaceutical leaders manage complex global dynamics, timely insight into industry trends and actionable opportunities has become critical for effective decision-making.

Market Snapshot: Thrombolytic Drug Market

The Thrombolytic Drug Market grew from USD 1.43 billion in 2024 to USD 1.69 billion in 2025. It is expected to continue growing at a CAGR of 17.85%, reaching USD 3.84 billion by 2030. Reflecting this strong expansion, industry participants face an environment shaped by urgent clinical need, regional policy developments, trade policy shifts, and new technology. Stakeholders including pharmaceutical manufacturers, healthcare providers, and supply chain partners must adapt business models to capture value across an increasingly segmented landscape.

Scope & Segmentation

This report offers granular coverage of the thrombolytic drug market with a strategic focus on high-growth opportunities, technology advancement, and global expansion. Structured market segmentation enables targeted forecasting and decision support:

  • Drug Class: Streptokinase, tissue plasminogen activators (alteplase, reteplase, tenecteplase), and urokinase represent the principal agent categories, each with distinct mechanisms and clinical use cases.
  • Therapeutic Indication: Acute myocardial infarction, deep vein thrombosis, ischemic stroke, and pulmonary embolism form core clinical drivers, requiring nuanced approaches to therapy selection and outcome measurement.
  • Route of Administration: Intra-arterial and intravenous routes offer flexibility for acute and chronic applications, with variation by care setting and procedural complexity.
  • End User: Hospitals, emergency medical services, and ambulatory centers are key segments, each prioritizing different operational efficiencies and patient care models.
  • Patient Group: Adult and pediatric cohorts require formulation stability, pharmacokinetic adaptation, and age-specific dosing strategies.
  • Geography: Americas (including key U.S. states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (highlighting both developed and emerging markets), and Asia-Pacific (with particular momentum in China, India, Japan, and Australia).
  • Company Profiles: In-depth analysis spans F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Sanofi S.A., Teva, Sandoz, Sun Pharma, Cipla, Apotex, Cadila, and Biocon.

Key Takeaways for Decision-Makers

  • Innovation in drug design and delivery has shifted treatment paradigms, introducing agents with extended half-lives and improved fibrin specificity, thus broadening clinical applications and offering flexible administration windows.
  • The adoption of digital tools and real-world evidence is enhancing precision in patient selection and dosing, enabling healthcare systems to drive personalized treatment strategies and improve outcomes.
  • Strategic partnerships among pharmaceutical innovators, diagnostic technology firms, and regulatory bodies are accelerating development timelines and optimizing commercialization pathways for novel therapeutics.
  • Regional differences in healthcare infrastructure, reimbursement policies, and regulatory frameworks generate unique opportunities and challenges, compelling manufacturers to tailor strategies for diverse markets.
  • Strong competition from generics and biosimilars is placing emphasis on value-based contracting, rapid-response protocols, and innovative service offerings to maintain market share and meet evolving provider expectations.

Tariff Impact on Supply Chain Resilience

Recent U.S. tariff adjustments on active pharmaceutical ingredients and finished thrombolytic drugs have increased the cost burden for manufacturers, prompting strategic shifts in sourcing and production footprints. The result is an increased focus on domestic capacity, buffering of inventories, and collaborative supplier relationships. Providers are responding through value-centric procurement and new funding models to safeguard patient access, especially for under-resourced populations.

Methodology & Data Sources

This research is based on a multi-method approach including comprehensive secondary analysis of peer-reviewed studies, clinical registries, and regulatory filings, combined with direct interviews involving key industry opinion leaders and executives. Quantitative benchmarking references proprietary databases, financial disclosures, and international trade data, validated and synthesized through internal peer review.

Why This Report Matters

  • Enables strategic planning by offering segment-specific intelligence across therapies, indications, and regional markets.
  • Supports risk mitigation and opportunity capture through actionable insights on regulatory shifts, digital transformation, and competitive landscape changes.
  • Delivers a data-driven foundation for portfolio development, partnership decisions, and market-entry strategies.

Conclusion

The thrombolytic drug market is positioned for significant transformation, with opportunities emerging from advancements in drug design, regional growth variations, and supply chain adaptation. Stakeholders equipped with focused, research-based insights will be best positioned to drive patient outcomes and achieve sustained market success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Thrombolytic Drug Market, by Drug Class
8.1. Introduction
8.2. Streptokinase
8.3. Tissue Plasminogen Activator
8.3.1. Alteplase
8.3.2. Reteplase
8.3.3. Tenecteplase
8.4. Urokinase
9. Thrombolytic Drug Market, by Indication
9.1. Introduction
9.2. Acute Myocardial Infarction
9.3. Deep Vein Thrombosis
9.4. Ischemic Stroke
9.5. Pulmonary Embolism
10. Thrombolytic Drug Market, by Route Administration
10.1. Introduction
10.2. Intra Arterial
10.3. Intravenous
11. Thrombolytic Drug Market, by End User
11.1. Introduction
11.2. Ambulatory Center
11.3. Emergency Medical Service
11.4. Hospital
12. Thrombolytic Drug Market, by Patient Group
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Americas Thrombolytic Drug Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Thrombolytic Drug Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Thrombolytic Drug Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche AG
16.3.2. Boehringer Ingelheim International GmbH
16.3.3. Sanofi S.A.
16.3.4. Teva Pharmaceutical Industries Limited
16.3.5. Sandoz International GmbH
16.3.6. Sun Pharmaceutical Industries Limited
16.3.7. Cipla Limited
16.3.8. Apotex Inc.
16.3.9. Cadila Healthcare Limited
16.3.10. Biocon Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. THROMBOLYTIC DRUG MARKET MULTI-CURRENCY
FIGURE 2. THROMBOLYTIC DRUG MARKET MULTI-LANGUAGE
FIGURE 3. THROMBOLYTIC DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. THROMBOLYTIC DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. THROMBOLYTIC DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. THROMBOLYTIC DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY STREPTOKINASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ALTEPLASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY RETEPLASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TENECTEPLASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY UROKINASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INTRA ARTERIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY AMBULATORY CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY EMERGENCY MEDICAL SERVICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL THROMBOLYTIC DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES THROMBOLYTIC DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 43. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 45. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. CANADA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 49. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 51. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. MEXICO THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 67. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 74. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 76. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. UNITED KINGDOM THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 80. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 82. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. GERMANY THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 86. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 88. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. FRANCE THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 92. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 94. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. RUSSIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 98. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 100. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. ITALY THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 104. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 106. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. SPAIN THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 110. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 112. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. UNITED ARAB EMIRATES THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 116. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 128. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 130. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. DENMARK THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 140. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 142. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. QATAR THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 146. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 147. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 148. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. FINLAND THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 152. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 154. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. SWEDEN THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 158. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 160. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. NIGERIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 164. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 165. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 166. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 167. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. EGYPT THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 170. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 172. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. TURKEY THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 176. ISRAEL THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. ISRAEL THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 178. ISRAEL THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. ISRAEL THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 182. NORWAY THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. NORWAY THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 184. NORWAY THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. NORWAY THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. NORWAY THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. NORWAY THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 188. POLAND THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. POLAND THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 190. POLAND THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. POLAND THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. POLAND THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. POLAND THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 194. SWITZERLAND THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 195. SWITZERLAND THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 196. SWITZERLAND THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 197. SWITZERLAND THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. SWITZERLAND THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. SWITZERLAND THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC THROMBOLYTIC DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 207. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 208. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 209. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. CHINA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 213. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 215. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. INDIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 219. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 221. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. JAPAN THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 231. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 233. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 243. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 244. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 245. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. THAILAND THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 267. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 268. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 269. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. VIETNAM THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 273. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 274. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, 2018-2030 (USD MILLION)
TABLE 275. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. TAIWAN THROMBOLYTIC DRUG MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 279. THROMBOLYTIC DRUG MARKET SHARE, BY KEY PLAYER, 2024
TABLE 280. THROMBOLYTIC DRUG MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Thrombolytic Drug market report include:
  • F. Hoffmann-La Roche AG
  • Boehringer Ingelheim International GmbH
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Cipla Limited
  • Apotex Inc.
  • Cadila Healthcare Limited
  • Biocon Limited

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.69 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.84 Billion
Compound Annual Growth Rate17.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Peripheral Arterial Disease Therapeutics Market by Product Type, Indication, End User, Route Of Administration - Global Forecast to 2030 - Product Image

Peripheral Arterial Disease Therapeutics Market by Product Type, Indication, End User, Route Of Administration - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Urokinase Market by Product Type, Form, Application, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Urokinase Market by Product Type, Form, Application, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Circle Acute Ischemic Stroke Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Circle Acute Ischemic Stroke Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Acute Ischemic Stroke- Pipeline Insight, 2025 - Product Image

Acute Ischemic Stroke- Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Stroke Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Stroke Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 130 Pages
  • Global
From

About the Thrombolytics Market

Thrombolytics are a class of cardiovascular drugs used to treat acute ischemic stroke, myocardial infarction, and pulmonary embolism. They work by breaking down the clot that is blocking the blood vessel, allowing blood to flow freely. Thrombolytics are typically administered intravenously, and can be used in combination with other treatments such as anticoagulants and antiplatelet drugs. The most commonly used thrombolytic is tissue plasminogen activator (tPA), which is a recombinant form of the naturally occurring enzyme plasminogen. The thrombolytics market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. Some of the major players in the market include Boehringer Ingelheim, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.